Last updated on December 2017

A Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-786 for the treatment of agitation in patients with dementia of the Alzheimer’s type.


Brief description of study

The study will evaluate the efficacy, safety, and tolerability of a medication: AVP-786 compared to
placebo, for the treatment of agitation in patients with dementia of the Alzheimer’s type.
Approximately 325 patients will be enrolled at approximately 50 centers in North America.

Clinical Study Identifier: TX154862

Contact Investigators or Research Sites near you

Start Over

Todd Morgan

Texas Neurology, PA
Dallas, TX USA
  Connect »